Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD
2006-005534-20Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of erdosteine in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Imperial College London. Primary endpoints: 8-isoprostanes in induced sputum and leukotriene B4 (LTB4) in induced sputum. Started Nov 2007; status: completed.
02
Drugs
erdosteine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-005534-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005534-20.